IOP Launches Second Generation Amniotic Membrane Technology

Print This Post

COSTA MESA, California – 15 September 2006 – IOP Inc., the premier developer and distributor of specialty tissue technologies for eye surgery, introduced AmbioDry2™ : the new, improved, generation 2 amniotic membrane technology for eye surgery.

ambio2 1 IOP Launches Second Generation Amniotic Membrane Technology

In 2002, the “generation 1″ AmbioDry™ Amniotic Membrane technology was introduced to the ophthalmic surgical community for the treatment of ocular disorders. Since then, AmbioDry™ has become recognized as the leading global amniotic membrane technology for eye surgery.

In comparison to the “generation 1″, AmbioDry2™ offers an array of improvements, advantages and benefits: preserved cellular and extracellular matrices; dehydrated for room temp storage; packaged sterile; improved visual identification of tissue orientation; substrate-free; superior tissue quality.

The use of dehydrated human amniotic membrane to surgically treat ocular surface disorders was initially detailed clinically by physicians in the 1940′s. During the past five years, its clinical use and reporting have been revived and expanded.

ambio2 2 IOP Launches Second Generation Amniotic Membrane Technology

Dr. Batlle, a world-renown ophthalmologist, is the recognized innovator and pioneer of preserved amniotic membrane for ophthalmic surgery. His efforts with amniotic membrane began in 1989. In 1993, at the American Academy Meeting in Chicago, Dr. Batlle initially presented his experiences employing preserved human amniotic membrane for the surgical treatment of pterygium, dermoids, fornix reconstruction, alkali burns and bullous keratopathy.

Most importantly, Dr. Batlle’s research noted the histological and immunological importance of utilizing preserved amniotic membrane containing devitalized, intact cellular components – to ensure graft viability and performance.

“Today marks a revolutionary step forward towards improving surgical performance and outcomes with processed amniotic membrane technology,”said Erich Ziegler, V.P of IOP. “The technological and utility advantages of the AmbioDry2™ technology, compared to current, alternative options, are significant. We must, and will, continue to innovate.”

About IOP

Founded in 1988, IOP, Inc. develops and commercializes specialized, leading-edge surgical technologies for eye surgery. IOP’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.

IOP currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for cornea, anterior and oculoplastic surgeries.

This entry was posted in News. Bookmark the permalink.

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>